ACADIA Pharmaceuticals Inc. (ACAD)

46.77
0.44 0.95
NASDAQ : Health Technology
Prev Close 46.33
Open 46.04
Day Low/High 45.90 / 47.30
52 Wk Low/High 14.01 / 47.79
Volume 419.17K
Avg Volume 2.06M
Exchange NASDAQ
Shares Outstanding 154.03M
Market Cap 6.97B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market leader candidate

ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference On May 13, 2015

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference On May 13, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

ACADIA Pharmaceuticals To Announce First Quarter Financial Results On May 7, 2015

ACADIA Pharmaceuticals To Announce First Quarter Financial Results On May 7, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving Acadia Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of May 12, 2015

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving Acadia Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of May 12, 2015

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased ACADIA Pharmaceuticals Inc.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Acadia Pharmaceuticals Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 12, 2015

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Acadia Pharmaceuticals Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 12, 2015

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common shares of Acadia Pharmaceuticals Inc.

'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets

'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets

Cramer likes Acadia Pharmaceuticals and prefers Schlumberger over U.S. Silica Holdings.

Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus

Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus

From earnings to activist investors, Cramer said investors need to focus on the good things now happening in the markets.

ACADIA Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference On April 14, 2015

ACADIA Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference On April 14, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

ACADIA Pharmaceuticals Appoints Daniel Soland To Board Of Directors

ACADIA Pharmaceuticals Appoints Daniel Soland To Board Of Directors

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In ACADIA Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

ACADIA Pharmaceuticals Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

ACADIA Pharmaceuticals Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

'Mad Money' Lightning Round: Dave and Buster's Is Too Risky for Me

'Mad Money' Lightning Round: Dave and Buster's Is Too Risky for Me

Cramer is staying away from Acadia Pharmaceuticals and thinks Bluebird Bio is overheating.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be listening and learning next week as Foot Locker, FedEx, Oracle and Darden report.

Buyers Get Back to Big-Caps

Market shows some love to overlooked groups.

Stocks Bounce Back After Two-Day Selloff as Fed Anxiety Eases

Stocks Bounce Back After Two-Day Selloff as Fed Anxiety Eases

The Dow climbed 260 points on Thursday, shooting higher on a rally among major U.S. banks.

Stocks Hold Onto Highs as Anxiety Over Looming Fed Rate Hike Eases

Stocks Hold Onto Highs as Anxiety Over Looming Fed Rate Hike Eases

Stocks look to erase the past two days of losses on Thursday, shooting higher on a rally among major U.S. banks.

Acadia Pharmaceuticals (ACAD) Stock Tanks Today on Delayed Regulatory Application

Acadia Pharmaceuticals (ACAD) Stock Tanks Today on Delayed Regulatory Application

Acadia Pharmaceuticals (ACAD) shares are down double digits after the company announced that it is delaying its application for regulatory approval of its Parkinson's disease treatment.

Stocks Rally as Banks Surge; Lumber Liquidators Shares Pop

Stocks Rally as Banks Surge; Lumber Liquidators Shares Pop

Stocks rally after two straight days of losses, led by the financial sector and a rebound in oil prices.

3 Stocks Reiterated As A Sell: FCX, ICPT, ACAD

3 Stocks Reiterated As A Sell: FCX, ICPT, ACAD

TheStreet Ratings team reiterated 3 stocks with a sell rating on Thursday

Stock Futures Post Modest Gains; Retail Sales Decline for Third Month

Stock Futures Post Modest Gains; Retail Sales Decline for Third Month

Stock futures post modest gains on Thursday morning in an attempted recovery after two days of losses which wiped out Wall Street's year-to-date gains.

Heavy Early Morning Activity On ACADIA Pharmaceuticals (ACAD)

Heavy Early Morning Activity On ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a pre-market mover with heavy volume candidate

ACADIA SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of ACADIA Pharmaceuticals Inc.

ACADIA SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of ACADIA Pharmaceuticals Inc.

Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of ACADIA Pharmaceuticals Inc.

Acadia Drug Is Delayed Again as CEO Announces Retirement

Acadia Drug Is Delayed Again as CEO Announces Retirement

Acadia admits that it can't seek approval for its Parkinson's psychosis drug this quarter, as promised. The company's CEO also resigned.

ACADIA Pharmaceuticals Announces Retirement Of Uli Hacksell, Ph.D., Chief Executive Officer

ACADIA Pharmaceuticals Announces Retirement Of Uli Hacksell, Ph.D., Chief Executive Officer

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals Updates Planned Timing Of NUPLAZIDTM NDA Submission

ACADIA Pharmaceuticals Updates Planned Timing Of NUPLAZIDTM NDA Submission

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

TheStreet Quant Rating: D (Sell)